Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study

被引：0
|
作者：
Pandya, Amit G. [1 ,2 ]
Ezzedine, Khaled [3 ,4 ]
Passeron, Thierry [5 ,6 ]
van Geel, Nanja [7 ]
Brown, Kurt [8 ]
Santos, Leandro [8 ]
Erskine, Lois [8 ]
Wagya, Kofi [8 ]
Blauvelt, Andrew [9 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
[2] Palo Alto Fdn Med Grp, Sunnyvale, CA USA
[3] Henri Mondor Univ Hosp, Paris, France
[4] Univ Paris Est Creteil Val de Marne, Paris, France
[5] Univ Cote Azur, Ctr Hosp Univ Nice, Nice, France
[6] Univ Cote Azur, INSERM U1065, C3M, Nice, France
[7] Ghent Univ Hosp, Ghent, Belgium
[8] Incyte Corp, Wilmington, DE USA
[9] Oregon Med Res Ctr, Portland, OR USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
JAK1; inhibitor; oral administration; INCB054707; repigmentation; vitiligo;
D O I：
10.1093/bjd/ljae266.094
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
721
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study
    Doerner, Thomas
    Bowman, Simon J.
    Fox, Robert
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Fisher, Benjamin A.
    Barcelos, Filipe
    De Vita, Salvatore
    Schulze-Koops, Hendrik
    Moots, Robert J.
    Junge, Guido
    Woznicki, Janice
    Sopala, Monika
    Avrameas, Alexandre
    Luo, Wen-Lin
    Hueber, Wolfgang
    ARTHRITIS & RHEUMATOLOGY, 2025,
  • [2] IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
    Dorner, T.
    Bowman, S. J.
    Fox, R.
    Mariette, X.
    Papas, A.
    Grader-Beck, T.
    Fisher, B. A.
    Barcelos, F.
    De Vita, S.
    Schulze-Koops, H.
    Moots, R. J.
    Junge, G.
    Woznicki, J.
    Sopala, M.
    Luo, W. L.
    Hueber, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 593 - 594
  • [3] IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
    Doerner, T.
    Bowman, S. J.
    Fox, R.
    Mariette, X.
    Papas, A.
    Grader-Beck, T.
    Fisher, B. A.
    Barcelos, F.
    De Vita, S.
    Schulze-Koops, H.
    Moots, R. J.
    Junge, G.
    Woznicki, J.
    Sopala, M.
    Luo, W.
    Hueber, W.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (12) : 87 - 88
  • [4] Ianalumab (VAY736) Safety and Efficacy in Patients with Sjogren's Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
    Doerner, Thomas
    Bowman, Simon J.
    Fox, Robert
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Fisher, Ben A.
    Barcelos, Filipe
    De Vita, Salvatore
    Schulze-Koops, Hendrik
    Moots, Robert
    Junge, Guido
    Woznicki, Janice
    Sopala, Monika
    Luo, Wen-Lin
    Hueber, Wolfgang
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2063 - 2065
  • [5] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Guttman-Yassky, Emma
    Bieber, Thomas
    Serra-Baldrich, Esther
    Simpson, Eric
    Rosmarin, David
    Elmaraghy, Hany
    Meskimen, Eric
    Natalie, Chitra R.
    Liu, Zhuqing
    Xu, Chenjia
    Pierce, Evangeline
    Morgan-Cox, MaryAnn
    Gil, Esther Garcia
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 740 - 748
  • [6] Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial
    Muir, A.
    Goodman, Z.
    Levy, C.
    Janssen, H.
    Montano-Loza, A.
    Bowlus, C.
    Ding, D.
    Jia, C.
    McColgan, B.
    Myers, R.
    Subramanian, M.
    McHutchison, J.
    Manns, M.
    Chapman, R.
    Afdhal, N.
    Eksteen, B.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S73 - S73
  • [7] Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
    Fisher, Benjamin A.
    Mariette, Xavier
    Papas, Athena S.
    Grader-Beck, Thomas
    Bootsma, Hendrika
    Ng, Wan-Fai
    Van Daele, Paul
    Finzel, Stephanie
    Elgueta, Sergio
    Hermann, Josef
    McCoy, Sara
    Bookman, Arthur
    Sopala, Monika
    Luo, Wen-Lin
    Scheurer, Cornelia
    Hueber, Wolfgang
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3242 - 3244
  • [8] Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
    Oakes, Tina Marie Myers
    Skljarevski, Vladimir
    Zhang, Qi
    Kielbasa, William
    Hodsdon, Michael E.
    Detke, Holland C.
    Camporeale, Angelo
    Saper, Joel R.
    CEPHALALGIA, 2018, 38 (06) : 1015 - 1025
  • [9] A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS
    Wei, J. C. C.
    Fleischmann, R. M.
    Morris, S.
    Polvent, E.
    Shen, Z.
    Roche, A. Clouser
    Hingorani, V.
    Yan, S.
    Yeh, L. T.
    Keenan, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 192 - 192
  • [10] Efficacy of povorcitinib for the treatment of vitiligo by patient demographics and baseline clinical characteristics: week 52 subgroup analysis from a randomized, placebo-controlled, phase 2b clinical trial
    Pandya, Amit G.
    Passeron, Thierry
    Blauvelt, Andrew
    van Geel, Nanja
    Brown, Kurt
    Erskine, Lois
    Xue, Zhenyi
    Ezzedine, Khaled
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 97 - 98
12345